Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Xiaofei Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9289-2215; OpenAlex author ID A5086497754. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

  1. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Co-author DOI 10.1080/21691401.2023.2264358↗
  2. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong-Juan Yao · 2 shared papers, 2022–2023 · strength 0.29
  2. Yuchen Shi · 2 shared papers, 2022–2023 · strength 0.29
  3. Liang Li · 2 shared papers, 2022–2023 · strength 0.29
  4. Hebing Chen · 2 shared papers, 2022–2023 · strength 0.29
  5. Xiaohong Liu · 1 shared paper, 2023 · strength 0.16
  6. Rong‐Guang Shao · 1 shared paper, 2022 · strength 0.13
  7. Rui Cao · 1 shared paper, 2022 · strength 0.13
  8. Yi Li · 1 shared paper, 2022 · strength 0.13
  9. Li Zhang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.